To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam Therapeutics Announces Acquisition of Guide ... Beam Therapeutics Launches with $87M Series A Beam, which remains some distance away from treating a patient with one of its medicines, is now worth a lofty $6.5 billion after its share price rose by 560% since an initial public offering last February. Beam Therapeutics Appoints Healthcare Industry Leader John ... A panel convened by the regulator suggested ways to make gene therapy research safer, but struggled to propose broader recommendations.
The company's portfolio comprises Gene Correction, Gene Modification . Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. The company expects to file an application with the FDA in the second half of this year to begin human testing of its first treatment. Those hurdles, however, haven't appeared to deter investors from pouring money into developers of gene editing treatments — a field that, while fast emerging, remains years behind the older technology used in gene replacement. Beam Therapeutics' project in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) approved by the state's Economic Investment Committee earlier today. Beam Therapeutics 5.10. Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021 Acquisition of Guide Therapeutics Supports Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing Team Bolstered by Appointment of Amy Simon, M.D., as Chief Medical Officer and Kate Walsh to Board of Directors Balance Sheet Strengthened by $260 Million Common Stock Investment CAMBRIDGE, Mass., March 15 . Beam Therapeutics announced today that it is launching to develop precision genetic medicines that make edits to individual base pairs in the genetic code. Beam Therapeutics Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-5238376 (State or other jurisdiction of incorporation or organization) . Sana CEO and president Steve Harr. Beam's proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. Beam Therapeutics CEO John Evans. Beam Therapeutics. In early December, Intellia capitalized on those stock gains to raise $200 million selling stock at a price of $36.50 per share. Both Beam and Verve use a different, more precise form of gene editing than the CRISPR-based approach used by CRISPR Therapeutics, Editas and Intellia. "This funding will allow us to further accelerate deployment of our advanced genome editing platform, which enables simple, flexible targeting of any site in a given genome, in a number of focus areas including therapeutic research and development, agricultural biotechnology and industrial biotechnology," Caribou CEO Rachel Haurwitz said in a . Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV. With its $135 million series B round announced Wednesday, Beam Therapeutics surpassed CRISPR Therapeutics AG (NASDAQ:CRSP) for the most venture funding raised by a CRISPR company. Beam Therapeutics announced today that it is launching to develop precision genetic medicines that make edits to individual base pairs in the genetic code. Founded in 2017, Massachusetts startup Beam Therapeutics has taken in $222 million in funding so far to develop a technology called "base editing" which focuses on precision gene-editing which replaces single letters (C, T, G, A) without inducing a double-strand DNA break. The company began trading Thursday on the Nasdaq under the ticker symbol BEAM. Reports cite, the amount raised in the latest financing round brings the total capital raised by the company within a year to $222 million. Beam's focusing first on advancing a base editing treatment for sickle cell disease and beta thalassemia, but also has an early-stage pipeline aimed at several liver and eye diseases as well as two types of cancer. At the J.P. Morgan Healthcare Conference earlier this month, the biotech unveiled new data showing its treatment led to durable reductions in both PCSK9 protein and LDL cholesterol levels in monkeys, results that support its preparations for human testing. About Beam TherapeuticsBeam Therapeutics Inc. (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our. Senators Duckworth and Durbin Announce $2M In Telehealth Funding For Illinois Healthcare. This enables a wide range of . NC. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal . Existing investors Wellington Management Company and Casdin Capital were joined in the latest round by a slate of nine venture funds, several of which also just committed to buying shares in Beam, too. Beam Therapeutics's main competitors include Omega Therapeutics, TES Pharma, NewStem and Canopy Biosciences. CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE . Inhalation Product Development for the Pharmaceutical Industry, Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here, The leading site for news and procurement in the pharmaceutical industry, “More than 50% of disease-causing genetic errors are due to a single-letter alteration in the nucleobases of the human genome.”, I consent to Verdict Media Limited (publisher of Pharmaceutical Technology) collecting my details provided via this form in accordance with the. This website uses cookies to ensure you get the best experience on our website. It is currently working on ten active programmes. Exploristics signs collaboration agreement with Renovion, using the cloud-based simulation ... Altasciences Expands Ligand Binding Laboratory to Meet High Demand for Bioanalytical Solutions. on Funding. . Dominant share in one disease is funding a deal to add gene-editing capabilities for Vertex Pharmaceuticals. This compares to loss of $0.69 per share a year ago. (Sana Photo) Sana Biotechnology has a new $50 million tool in its toolbox. We use cookies to optimize your experience on our website and for analytics and advertising purposes. Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues. Although Beam did not lay out any specifics regarding its primary disease research, the company said it will focus its research on multiple DNA base editor platforms that were developed in the Harvard . Our Japan Ventures portfolio company, Beam Therapeutics, has today announced it has raised $135m in Series B funding.It plans to use this funding to advance the company's development of next-generation CRISPR technologies, expand its pipeline of base editing programmes and further extend its scientific and technical leadership. Redmile Group, Cormorant Asset Management, GV and Altitude Life Science Ventures participated in the financing round, which was joined by F-Prime Capital, ARCH Venture Partners, Eight Roads Ventures, Omega Funds and other undisclosed investors. Beam, which this year expects to ask the Food and Drug Administration to begin studies of its lead gene editing therapy in humans, anticipates using the new funds to support clinical testing as well to pursue "strategic partnerships." On Tuesday, Beam Therapeutics and Verve Therapeutics, two high-profile biotechs based in Cambridge, Massachusetts, each announced new investments. READ. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues. "Beam Therapeutics is developing precision genetic medicines through base editing. Verve is earlier in development, but similarly expects the cash it raised to help advance its lead gene editing treatment. Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.78. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal . Refuge Biotechnologies. Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the successful completion of a. . BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Also Underway CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base . About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. (Verve is a private company.). NEW YORK (GenomeWeb) - Beam Therapeutics announced today that it has launched with $87 million in Series A funding to develop precision genetic medicines that make edits to individual base pairs in the genome. A Gene Editing IPO from Beam Therapeutics. The aggregate gross proceeds to Beam Therapeutics from the offering were higher than expected, reaching approximately $207 million, before deducting underwriting discounts and commissions and other offering expenses. Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Cambridge, Mass. Company Overview